AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Ksl diagnostics results2/18/2024 ![]() Hanover, New Hampshire-based MiTest was formed out of a research partnership between Dartmouth Hitchcock Medical Center and Cedars-Sinai Medical Center and it developed the test that became CDPath in 2014. San Diego-based Prometheus, a specialty clinical laboratory developing tests focused on gastroenterology, has received New York State approval for the assay as a laboratory-developed test and will be processing the tests and reporting results to physicians. It is for differentiating these patients who may need more aggressive treatments from those who may not need treatment at all that Takeda developed and validated the CDPath test in partnership with Prometheus Laboratories and MiTest Health. ![]() Some patients have years of mild symptoms such as diarrhea and stomachache while others spiral into painful and destructive complications such as fistulas, abscesses, and strictures. The prescription-only test delivers results in about one week, said Tokyo-based Takeda, whose US business is headquartered in Boston.Ĭrohn's is an incurable inflammatory bowel disease with recurring cycles of flare-ups and remission. It is intended for use in patients at least 18 years old who have been diagnosed with Crohn's within the prior 10 years and have no history of bowel strictures, internal penetrating disease, or non-perianal surgery. The company said the CDPath blood test uses serologic markers of anti- Saccharomyces cerevisiae antibodies, immunoglobulin A/G isotypes, anti-CBir1 IgG, and perinuclear antineutrophil cytoplasmic antibodies along with the genetic marker NOD2 1007 frameshift mutation, and Crohn's disease history to rank a patient's risk of developing serious complications within three years, with findings that are presented to patients through a graphical interface. NEW YORK - Takeda has launched its CDPath prognostic assay in the US aimed at helping Crohn's disease patients understand the severity of their diagnoses and make better decisions on how to manage symptoms and disease progression.
0 Comments
Read More
Leave a Reply. |